Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 4:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 387 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Levosalbutamol/levalbuterol Clear all
Completed Phase 4 Interventional Results available

Effects of a Orally Inhaled Fluticasone Furoate on Growth Velocity in Prepubertal, Paediatric Subjects With Asthma Over a Year

NCT02889809
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone furoate, Placebo, Montelukast, Short Acting Beta 2 Agonist
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
5 Years to 9 Years
Enrollment
477 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
18
States / cities
Little Rock, Arkansas • Huntington Beach, California • Homestead, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2024 · Synced Oct 6, 2026, 4:33 PM EDT
Completed Phase 2 Interventional Results available

A Dose-ranging Study to Evaluate Albuterol and Hydrofluoroalkane in Subjects Ages 12 and Older With Persistent Asthma

NCT01058863
View directory record Official record
Conditions
Asthma
Interventions
Albuterol Spiromax®, ProAir® HFA, Placebo Inhaler
Drug · Other
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
13
States / cities
Huntington Beach, California • Rolling Hills Est., California • San Diego, California + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Oct 6, 2026, 4:33 PM EDT
Terminated Not applicable Interventional

Recovery After Dialysis-Requiring Acute Kidney Injury

NCT03305549
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
Conservative dialysis strategy, TIW dialysis strategy
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 100 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 19, 2025 · Synced Oct 6, 2026, 4:33 PM EDT
Completed Phase 3 Interventional Results available

Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With Chronic Obstructive Pulmonary Disease (COPD)

NCT03256695
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Albuterol sulfate (ABS)
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
40 Years and older
Enrollment
405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
40
States / cities
Andalusia, Alabama • Anniston, Alabama • Mobile, Alabama + 34 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Oct 6, 2026, 4:33 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Efficacy of Albuterol in Individuals With Late-onset Pompe Disease

NCT01885936
View directory record Official record
Conditions
Pompe Disease
Interventions
Albuterol, Placebo
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 15, 2019 · Synced Oct 6, 2026, 4:33 PM EDT
Withdrawn Not applicable Interventional

Medicated Aerosol Delivery Using A Jet Nebulizer Versus A Vibrating Mesh Nebulizer in COPD Exacerbation

NCT03051971
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Vibrating Mesh Nebulizer, Jet Nebulizer
Device
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
40 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Oct 27, 2021 · Synced Oct 6, 2026, 4:33 PM EDT
Terminated Not applicable Interventional

Symptom Based Performance of Airway Clearance After Starting Highly Effective Modulators for Cystic Fibrosis (SPACE-CF)

NCT05392855
View directory record Official record
Conditions
Cystic Fibrosis, Mucociliary Clearance Defect
Interventions
Symptom driven performance of airway clearance, Continuous daily performance of airway clearance
Other
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 20, 2024 · Synced Oct 6, 2026, 4:33 PM EDT
Completed Phase 1 Interventional

Study to Determine the Pharmacokinetics and Tolerability of Fluticasone Propionate MDPI and Fluticasone Propionate/Salmeterol MDPI Compared to High Strength FLOVENT® DISKUS® and ADVAIR® DISKUS® in Patients With Persistent Asthma 12 Years of Age and Older

NCT02437604
View directory record Official record
Conditions
Asthma
Interventions
Treatment A: Fp MDPI, Treatment B: FS MDPI, Treatment C Flovent, Treatment D: Advair
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
3
States / cities
Raleigh, North Carolina • Edmond, Oklahoma • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Oct 6, 2026, 4:33 PM EDT
Recruiting Phase 4 Interventional

Ventilation and Perfusion in Asthmatics

NCT07426458
View directory record Official record
Conditions
Asthma
Interventions
Albuterol Sulfate, Albuterol-Budesonide
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 6, 2026, 4:33 PM EDT
Completed Phase 4 Interventional

Chronic Obstructive Pulmonary Disease Endpoints Study

NCT00358358
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Fluticasone Propionate/Salmeterol 500/50mcg combination, Fluticasone Propionate 500mcg, Salmeterol 50mcg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
4
States / cities
Absecon, New Jersey • Charleston, South Carolina • Greenville, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2017 · Synced Oct 6, 2026, 4:33 PM EDT
Completed Phase 4 Interventional

Study to Investigate Changes in Airway Inflammation, Symptoms, and Rescue Therapy Utilization With AIRSUPRA Compared to Albuterol as Needed in Adults With Mild Asthma

NCT06563102
View directory record Official record
Conditions
Mild Asthma
Interventions
Albuterol/Budesonide, Albuterol
Combination Product
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 120 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
16
States / cities
Phoenix, Arizona • Tucson, Arizona • Lancaster, California + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 6, 2026, 4:33 PM EDT
Completed No phase listed Observational

Replication of the POET-COPD Trial in Healthcare Claims Data

NCT05083429
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Salmeterol, Tiotropium
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
40 Years to 120 Years
Enrollment
8,716 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 6, 2026, 4:33 PM EDT
Completed Phase 2 Interventional

Dose Response Study of Levalbuterol in the Prevention of Exercise Induced Bronchoconstriction Compared to Racemic Albuterol in Pediatric Subjects

NCT00685347
View directory record Official record
Conditions
Asthma, Bronchoconstriction
Interventions
Levalbuterol HFA MDI, Racemic Albuterol
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
6 Years to 11 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003
U.S. locations
6
States / cities
Long Beach, California • Denver, Colorado • Englewood, Colorado + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2012 · Synced Oct 6, 2026, 4:33 PM EDT
Completed Not applicable Interventional Results available

Sub-Sensitivity to Long-Acting Bronchodilators (LABA)

NCT01117116
View directory record Official record
Conditions
Asthma
Interventions
fluticasone propionate and salmeterol, budesonide and formoterol
Drug
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 6, 2026, 4:33 PM EDT
Completed Phase 3 Interventional

Survival Of Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT00268216
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Salmeterol 50mcg/ Fluticasone Propionate 500mcg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 80 Years
Enrollment
6,228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
190
States / cities
Birmingham, Alabama • Jasper, Alabama • Mobile, Alabama + 152 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2017 · Synced Oct 6, 2026, 4:33 PM EDT
Completed Not applicable Interventional Results available

Aerosolized Albuterol Use in Severe BPD

NCT02766673
View directory record Official record
Conditions
Severe Bronchopulmonary Dysplasia
Interventions
Albuterol Sulfate, Sterile Saline
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
Up to 1 Year
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 6, 2026, 4:33 PM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Efficacy of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25 mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50 mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT01706328
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
FF/VI 100/25 Inhalation Powder NDPI, Fluticasone Propionate/Salmeterol 250/50 Inhalation Powder ACCUHALER/DISKUS, Placebo Inhalation Powder NDPI, Placebo Inhalation Powder ACCUHALER/DISKUS, Salbutamol as needed
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
828 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
16
States / cities
Clearwater, Florida • DeLand, Florida • Coeur d'Alene, Idaho + 13 more
Source: ClinicalTrials.gov public record
Updated May 2, 2018 · Synced Oct 6, 2026, 4:33 PM EDT
Completed Not applicable Interventional

Clinical Endpoint Bioequivalence Study of Fluticasone Propionate & Salmeterol Xinafoate (100μg/50μg)

NCT03535870
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone propionate/salmeterol, Advair Diskus, 100 Mcg-50 Mcg Inhalation Powder, Placebo
Drug
Lead sponsor
West-Ward Pharmaceutical
Industry
Eligibility
12 Years to 65 Years
Enrollment
1,556 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Nov 29, 2019 · Synced Oct 6, 2026, 4:33 PM EDT
Completed Phase 4 Interventional Results available

Phase IV Study in Asthma Subjects for Dry Powder Inhaler (DPI) Versus (vs) Metered Dose Inhaler (MDI) Correct Use

NCT02794480
View directory record Official record
Conditions
Asthma
Interventions
ELLIPTA DPI, GSK MDI, AZ MDI
Device
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
20
States / cities
Huntington Beach, California • Aventura, Florida • Clearwater, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2019 · Synced Oct 6, 2026, 4:33 PM EDT
Completed Phase 2 Interventional

Escalating and Cumulative-Dose Study of Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety of A006

NCT01189396
View directory record Official record
Conditions
Asthma, Bronchospasm, Chronic Obstructive Pulmonary Disease (COPD)
Interventions
A006, Placebo DPI, Proventil-HFA
Drug
Lead sponsor
Amphastar Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
4
States / cities
Medford, Oregon • Portland, Oregon • San Antonio, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 6, 2026, 4:33 PM EDT
Completed Not applicable Interventional Results available

Phase I Assessment of Hypertonic Saline in Moderate to Severe Asthmatics

NCT03556683
View directory record Official record
Conditions
Moderate to Severe Asthma
Interventions
3% Hypertonic Saline, 7% Hypertonic Saline, Salbutamol
Device · Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 60 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Oct 6, 2026, 4:33 PM EDT
Terminated Phase 3 Interventional

Controlled, 12-Week Study of Albuterol HFA Versus the Active Control, Proventil(R)-HFA in Asthmatic Patients

NCT00635505
View directory record Official record
Conditions
Asthma
Interventions
albuterol HFA (Armstrong's), albuterol HFA (Proventil HFA), HFA placebo
Drug
Lead sponsor
Amphastar Pharmaceuticals, Inc.
Industry
Eligibility
12 Years to 75 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
42
States / cities
Mobile, Alabama • Huntington Beach, California • Long Beach, California + 34 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2013 · Synced Oct 6, 2026, 4:33 PM EDT
Completed Phase 2 Interventional Results available

Evaluation of SAR440340 and as Combination Therapy With Dupilumab in Moderate-to-Severe Asthma Participants

NCT03387852
View directory record Official record
Conditions
Asthma
Interventions
SAR440340, Dupilumab, Fluticasone or Fluticasone/salmeterol combination, Placebo for SAR440340, Placebo for dupilumab
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 70 Years
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
18
States / cities
Birmingham, Alabama • Long Beach, California • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2022 · Synced Oct 6, 2026, 4:33 PM EDT
Terminated Phase 3 Interventional

Tiotropium/Salmeterol Inhalation Powder (Spiriva Handihaler and Salmeterol Polyethylene (PE) Capsule) in Chronic Obstructive Pulmonary Disease (COPD)

NCT00662740
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Tiotropium/Salmeterol QD, Placebo, Salmeterol, Tiotropium/Salmeterol QD+ Salmeterol, Tiotropium (Spiriva®)
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
20
States / cities
Boulder, Colorado • Wheat Ridge, Colorado • Winter Park, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2023 · Synced Oct 6, 2026, 4:33 PM EDT